[go: up one dir, main page]

HK1042850A1 - An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport. - Google Patents

An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport.

Info

Publication number
HK1042850A1
HK1042850A1 HK02104408A HK02104408A HK1042850A1 HK 1042850 A1 HK1042850 A1 HK 1042850A1 HK 02104408 A HK02104408 A HK 02104408A HK 02104408 A HK02104408 A HK 02104408A HK 1042850 A1 HK1042850 A1 HK 1042850A1
Authority
HK
Hong Kong
Prior art keywords
inhibitor compound
bile acid
ileum
administering
acid transport
Prior art date
Application number
HK02104408A
Other languages
English (en)
Inventor
Bertil Abrahamsson
Ann-Margret Lindqvist
Anna-Lena Ungell
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1042850A1 publication Critical patent/HK1042850A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK02104408A 1999-04-19 2002-06-12 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport. HK1042850A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9901387A SE9901387D0 (sv) 1999-04-19 1999-04-19 New pharmaceutical foromaulations
PCT/SE2000/000755 WO2000062810A1 (en) 1999-04-19 2000-04-19 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport

Publications (1)

Publication Number Publication Date
HK1042850A1 true HK1042850A1 (en) 2002-08-30

Family

ID=20415263

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02104408A HK1042850A1 (en) 1999-04-19 2002-06-12 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport.

Country Status (27)

Country Link
EP (1) EP1173205B1 (xx)
JP (1) JP2002542208A (xx)
KR (1) KR20010108516A (xx)
CN (1) CN1348384A (xx)
AT (1) ATE296641T1 (xx)
AU (1) AU767425B2 (xx)
BR (1) BR0009835A (xx)
CA (1) CA2379105A1 (xx)
CZ (1) CZ20013743A3 (xx)
DE (1) DE60020551T2 (xx)
DK (1) DK1173205T3 (xx)
EE (1) EE04607B1 (xx)
ES (1) ES2241603T3 (xx)
HK (1) HK1042850A1 (xx)
HU (1) HUP0200793A3 (xx)
IL (1) IL145871A0 (xx)
IS (1) IS2161B (xx)
NO (1) NO20015063L (xx)
NZ (1) NZ514264A (xx)
PL (1) PL351186A1 (xx)
PT (1) PT1173205E (xx)
SE (1) SE9901387D0 (xx)
SI (1) SI1173205T1 (xx)
SK (1) SK15282001A3 (xx)
TR (1) TR200103033T2 (xx)
WO (1) WO2000062810A1 (xx)
ZA (1) ZA200108539B (xx)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
ES2298236T3 (es) * 2001-01-31 2008-05-16 Evonik Rohm Gmbh Forma medicamentosa de particulas multiples, que contiene por lo menos dos formas de granulos, revestidas de manera diferente.
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
AU2002329387B2 (en) 2001-09-08 2007-06-07 Albireo Ab Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment hyperlipidaemia
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0216321D0 (en) * 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
US8227439B2 (en) 2008-05-15 2012-07-24 Morphotek, Inc. Treatment of metastatic tumors
WO2010062863A2 (en) 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Compositions containing satiogens and methods of use
WO2010062861A2 (en) 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
GB0900350D0 (en) * 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
CN102844044B (zh) 2010-02-04 2016-10-26 摩尔弗泰克有限公司 氯毒素多肽和结合物及其应用
WO2011142858A2 (en) 2010-05-11 2011-11-17 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates, and methods for their use
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
JP5889321B2 (ja) 2010-11-04 2016-03-22 アルビレオ アクチエボラグ 肝疾患の処置用のｉｂａｔ阻害剤
DK2637646T3 (en) * 2010-11-08 2016-08-29 Albireo Ab PHARMACEUTICAL COMBINATION CONTAINING AN IBAT inhibitor and a bile acid binder
EP3278796A1 (en) * 2011-10-28 2018-02-07 Lumena Pharmaceuticals LLC Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
BR112014010223B8 (pt) * 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
JP2016505826A (ja) 2012-12-10 2016-02-25 フレッド ハッチンソン キャンサー リサーチ センター スクリーニングの方法
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
JP6751020B2 (ja) 2014-06-25 2020-09-02 Ｅａファーマ株式会社 固形製剤及びその着色防止又は着色低減方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
CN105362244A (zh) * 2015-11-26 2016-03-02 青岛海之源智能技术有限公司 考来烯胺缓释片及制备方法
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
RU2750937C2 (ru) 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
EP3413877B1 (en) 2016-02-09 2021-04-07 Albireo AB Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
AU2017250359B2 (en) 2016-04-15 2022-06-16 Blaze Bioscience, Inc. Methods of treating breast cancer
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
WO2019032027A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
MX2020013839A (es) 2018-06-20 2021-03-25 Albireo Ab Formulacion farmaceutica de odevixibat.
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
PT3921028T (pt) 2019-02-06 2023-02-15 Albireo Ab Compostos de benzotiadiazepina e a sua utilização como moduladores de ácido biliar
ES2955799T3 (es) 2019-02-06 2023-12-07 Albireo Ab Compuestos de benzotiazepina y su uso como moduladores de los ácidos biliares
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
AU2020223022A1 (en) 2019-02-12 2021-09-02 Mirum Pharmaceuticals, Inc. Methods for increasing growth in pediatric subjects having cholestatic liver disease
US20210046011A1 (en) 2019-08-12 2021-02-18 Massachusetts Institute Of Technology Articles and methods for administration of therapeutic agents
PT4069360T (pt) 2019-12-04 2024-03-06 Albireo Ab Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CR20220315A (es) 2019-12-04 2022-10-26 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar
AR120674A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiazepina y su uso como ácido biliar
AR120682A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
CA3158276A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
EP4069361B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
AR120683A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
CN114761018A (zh) 2019-12-04 2022-07-15 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES3002777T3 (en) 2020-08-03 2025-03-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
KR20230106651A (ko) 2020-11-12 2023-07-13 알비레오 에이비 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
JP2024500309A (ja) 2020-12-04 2024-01-09 アルビレオ エービー ベンゾチア（ジ）アゼピン化合物および胆汁酸モジュレータとしてのその使用
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
CN119053330A (zh) 2022-04-22 2024-11-29 阿尔比里奥公司 皮下给药asbt抑制剂
CN119343140A (zh) 2022-06-09 2025-01-21 阿尔比里奥公司 治疗肝炎
AU2023304672A1 (en) 2022-07-05 2025-01-02 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US20240207286A1 (en) 2022-12-09 2024-06-27 Albireo Ab Asbt inhibitors in the treatment of renal diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA941003B (en) * 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
TW289020B (xx) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤

Also Published As

Publication number Publication date
DE60020551D1 (de) 2005-07-07
KR20010108516A (ko) 2001-12-07
CZ20013743A3 (cs) 2002-01-16
EP1173205A1 (en) 2002-01-23
EE04607B1 (et) 2006-04-17
CN1348384A (zh) 2002-05-08
PL351186A1 (en) 2003-03-24
ZA200108539B (en) 2003-01-17
IL145871A0 (en) 2002-07-25
ES2241603T3 (es) 2005-11-01
DE60020551T2 (de) 2006-03-23
CA2379105A1 (en) 2000-10-26
ATE296641T1 (de) 2005-06-15
NO20015063D0 (no) 2001-10-18
AU767425B2 (en) 2003-11-13
SI1173205T1 (en) 2005-10-31
DK1173205T3 (da) 2005-08-08
BR0009835A (pt) 2002-01-08
HUP0200793A2 (hu) 2002-07-29
EE200100545A (et) 2003-02-17
EP1173205B1 (en) 2005-06-01
SK15282001A3 (sk) 2002-04-04
SE9901387D0 (sv) 1999-04-19
PT1173205E (pt) 2005-10-31
AU4633500A (en) 2000-11-02
IS2161B (is) 2006-11-15
HUP0200793A3 (en) 2004-07-28
NO20015063L (no) 2001-10-18
TR200103033T2 (tr) 2002-03-21
NZ514264A (en) 2003-10-31
JP2002542208A (ja) 2002-12-10
WO2000062810A1 (en) 2000-10-26
IS6109A (is) 2001-10-16

Similar Documents

Publication Publication Date Title
HK1042850A1 (en) An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport.
SE0003766D0 (sv) Novel formulation
BG105568A (en) Pharmaceutical compositions for modified release of an insulin sensitiser and another antidiabetic agent
NZ514574A (en) Novel method of treatment
BG66114B1 (bg) Многофазов състав на дросперидон като контрацептив
IL134778A0 (en) Pharmaceutical compositions for oral administration of molecular iodine
IL124459A0 (en) Antagonists of gonadotropin releasing hormone
GEP20022784B (en) Celecoxib Composition
MY118156A (en) Oral compositions of levosimendan.
GB0406384D0 (en) Composition for reducing appetite in mammals comprising proxyanidin
BG106057A (en) Method of enhancing the efficacy of anti-tumour agents
EP1007055A4 (en) METHODS OF ADMINISTERING AMIFOSTINE
TW349865B (en) Therapeutic agent for hemorrhoidal diseases
TW200505436A (en) Modified release pharmaceutical compositions and the processes for preparing them
JP2002500181A5 (xx)
EP1347754A4 (en) COMPOSITIONS FOR PREVENTION OF ADHESION
AU2003241629A1 (en) An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
CA2329665A1 (en) Treatment of depression and pharmaceutical preparations therefor
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
UA28031C2 (uk) Лікарська форма похідних 5- нітроімідазолу, фармацевтична композиція для лікування паразитарних та інфекційних захворювань шлунково-кишкового тракту, гастрозахищені мікрогранули похідних 5-нітроімідазолу, мікрогранули поkідних 5-нітроімідазолу з пролонгов
AU1305999A (en) (+)-ephedrine as a sympathomimetic drug
MY132962A (en) Inotropic agents with negative chronotropic and vasodilatory effects
UA36576A (uk) Спосіб корекції реактивності організму у хворих на інфаркт міокарда в гострому та підгострому періодах
MX9804819A (es) Antagonistas de hormona liberadora de gonadotropina.
UA4313U (uk) Спосіб лікування системного червоного вовчака

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090419